DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response
暂无分享,去创建一个
N. Bartonicek | A. Swarbrick | N. Deng | Sunny Z. Wu | Ghamdan Al-Eryani | D. Roden | S. Junankar | Jessica Yang | Chia-Ling Chan | B. Parker | D. Zanker | Louise A. Baldwin | G. Al-Eryani
[1] D. Hanahan. Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.
[2] Gary D Bader,et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells , 2020, Nature.
[3] Ryan D. Chow,et al. CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. , 2020, Cancer discovery.
[4] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[5] P. Robson,et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer , 2020, Nature Cancer.
[6] Zhiyong Guo,et al. Upregulated Seizure-Related 6 Homolog-Like 2 Is a Prognostic Predictor of Hepatocellular Carcinoma , 2020, Disease markers.
[7] Xiaozhong Wang,et al. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells , 2020, Nature Communications.
[8] P. Hertzog,et al. Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer , 2020, Clinical & translational immunology.
[9] E. Winer,et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[10] J. Herman,et al. Epigenetic heterogeneity in cancer , 2019, Biomarker Research.
[11] F. Rossi,et al. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs , 2019, Breast Cancer Research.
[12] Martin L. Miller,et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma , 2019, Cell.
[13] T. Aittokallio,et al. Improved detection of differentially represented DNA barcodes for high-throughput lineage phenomics , 2019, bioRxiv.
[14] Jeffrey T. Chang,et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state , 2019, Science Translational Medicine.
[15] Daniel L. Cameron,et al. Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer , 2019, Nature Communications.
[16] S. Miller,et al. Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis , 2019, Brain : a journal of neurology.
[17] M. Kunitski,et al. Double-slit photoelectron interference in strong-field ionization of the neon dimer , 2018, Nature Communications.
[18] P. Bousso,et al. The immune system profoundly restricts intratumor genetic heterogeneity , 2018, Science Immunology.
[19] Jeffrey T. Chang,et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer , 2018, Nature Communications.
[20] F. Marincola,et al. Evolution of Metastases in Space and Time under Immune Selection , 2018, Cell.
[21] Timothy A. Chan,et al. The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.
[22] G. Freeman,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[23] Ziwei Wang,et al. HOXA5 is a tumor suppressor gene that is decreased in gastric cancer , 2018, Oncology reports.
[24] Wyeth W. Wasserman,et al. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer , 2018, Cell.
[25] Aroop Sircar,et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β , 2018, Science Translational Medicine.
[26] Zlatko Trajanoski,et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution , 2018, Nature Communications.
[27] C. Zahnow,et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer , 2018, Nature Communications.
[28] Angela E. Leek,et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.
[29] Feng Zhang,et al. Identification of essential genes for cancer immunotherapy , 2017, Nature.
[30] V. Chekhonin,et al. Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer , 2017, Scientific Reports.
[31] John G. Doench,et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.
[32] H. Ljunggren,et al. Natural killer cell-mediated immunosurveillance of human cancer. , 2017, Seminars in immunology.
[33] Aaron T. L. Lun,et al. No counts, no variance: allowing for loss of degrees of freedom when assessing biological variability from RNA-seq data , 2017, Statistical applications in genetics and molecular biology.
[34] M. Thangaraju,et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade , 2017, Nature Communications.
[35] Zhiping Weng,et al. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. , 2017, Gastroenterology.
[36] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[37] L. Ellies,et al. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis , 2017, Oncoimmunology.
[38] Carlos Caldas,et al. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study , 2016, PLoS medicine.
[39] D. Felsher,et al. MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.
[40] C. Zahnow,et al. Combining Epigenetic and Immunotherapy to Combat Cancer. , 2016, Cancer research.
[41] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[42] Michael A. Langston,et al. EntropyExplorer: an R package for computing and comparing differential Shannon entropy, differential coefficient of variation and differential expression , 2015, BMC Research Notes.
[43] S. Loi,et al. Relevance of tumor-infiltrating lymphocytes in breast cancer , 2015, BMC Medicine.
[44] Steffen Dickopf,et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis , 2015, Nature.
[45] Joshua M. Korn,et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding , 2015, Nature Medicine.
[46] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[47] P. Hauser,et al. Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression , 2014, PloS one.
[48] P. Argani,et al. Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78 , 2013, Clinical Cancer Research.
[49] Weisan Chen,et al. An optimized method for establishing high purity murine CD8+ T cell cultures. , 2013, Journal of immunological methods.
[50] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[51] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[52] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[53] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[54] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[55] E. Mardis,et al. Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.
[56] S. Hochreiter,et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate , 2012, Nucleic acids research.
[57] F. Bertucci,et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.
[58] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[59] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[60] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[61] J. Paul,et al. New Dimensions , 2011 .
[62] E. Birney,et al. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.
[63] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[64] Lloyd J. Old,et al. Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.
[65] L. Zitvogel,et al. Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.
[66] Yusuke Nakamura,et al. Characterization of SEZ6L2 cell‐surface protein as a novel prognostic marker for lung cancer , 2006, Cancer science.
[67] D. Middleton,et al. Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.
[68] G. Collins. The next generation. , 2006, Scientific American.
[69] M. Cristofanilli. Circulating Tumor Cells in Patients With Breast Cancer Dormancy , 2005 .
[70] Tanja Fehm,et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.
[71] V. Cicinnati,et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope , 2000, Gene Therapy.
[72] J. Altman,et al. Mouse CD94/NKG2A Is a Natural Killer Cell Receptor for the Nonclassical Major Histocompatibility Complex (MHC) Class I Molecule Qa-1b , 1998, The Journal of experimental medicine.
[73] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.